|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1018 |
Guru Rank Value : 0.1 |
Guru Occurances : 4 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
714 |
160,302 |
276,407 |
571,147 |
Total Sell Value |
$64,260 |
$13,335,112 |
$23,824,420 |
$53,365,721 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
11 |
22 |
49 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wood Mark |
VP, Human Resources |
|
2008-01-22 |
4 |
AS |
$35.00 |
$108,424 |
D/D |
(2,990) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2008-01-22 |
4 |
OE |
$6.13 |
$40,337 |
D/D |
2,990 |
2,990 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-01-02 |
4 |
AS |
$35.28 |
$540,978 |
D/D |
(15,000) |
7,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2008-01-02 |
4 |
OE |
$6.46 |
$96,900 |
D/D |
15,000 |
22,213 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2008-01-02 |
4 |
AS |
$35.28 |
$451,061 |
D/D |
(12,500) |
10,000 |
|
- |
|
Swiedler Stuart J |
SVP, Clinical Affairs |
|
2008-01-02 |
4 |
OE |
$6.13 |
$76,625 |
D/D |
12,500 |
22,500 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev |
|
2008-01-02 |
4 |
AS |
$35.28 |
$180,398 |
D/D |
(5,000) |
7,034 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev |
|
2008-01-02 |
4 |
OE |
$7.16 |
$35,800 |
D/D |
5,000 |
12,034 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-12-21 |
4 |
AS |
$35.82 |
$220,474 |
D/D |
(6,114) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-12-21 |
4 |
OE |
$6.13 |
$94,494 |
D/D |
6,114 |
6,114 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2007-12-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
86,164 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-12-17 |
4 |
AS |
$35.15 |
$532,934 |
D/D |
(15,000) |
7,213 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-12-17 |
4 |
OE |
$6.46 |
$96,900 |
D/D |
15,000 |
22,213 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-11-21 |
4 |
AS |
$25.27 |
$61,155 |
D/D |
(2,365) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-11-21 |
4 |
OE |
$6.13 |
$29,517 |
D/D |
2,365 |
2,365 |
|
- |
|
Kakkis Emil D |
Chief Medical Officer |
|
2007-10-31 |
4 |
B |
$6.92 |
$14,101 |
D/D |
2,038 |
96,164 |
2.74 |
- |
|
Baffi Robert |
SVP, Technical Operations |
|
2007-10-31 |
5 |
B |
$6.92 |
$10,766 |
D/D |
1,556 |
34,680 |
|
- |
|
Davis George Eric |
VP, General Counsel |
|
2007-10-31 |
5 |
B |
$6.92 |
$9,617 |
D/D |
1,390 |
3,997 |
|
- |
|
Cooper Jeffrey H |
SVP, Chief Financial Officer |
|
2007-10-31 |
5 |
B |
$13.95 |
$14,019 |
D/D |
1,005 |
1,005 |
|
- |
|
Aselage Steve |
SVP, Global Commercial Dev |
|
2007-10-31 |
4 |
AB |
$6.92 |
$14,800 |
D/D |
2,139 |
7,034 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2007-10-31 |
4 |
AB |
$6.92 |
$3,584 |
D/D |
518 |
7,213 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-10-24 |
4 |
AS |
$26.00 |
$21,658 |
D/D |
(833) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-10-24 |
4 |
OE |
$17.54 |
$14,611 |
D/D |
833 |
833 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-10-22 |
4 |
AS |
$25.00 |
$38,763 |
D/D |
(1,532) |
0 |
|
- |
|
Wood Mark |
VP, Human Resources |
|
2007-10-22 |
4 |
OE |
$6.13 |
$14,902 |
D/D |
1,532 |
1,532 |
|
- |
|
1213 Records found
|
|
Page 42 of 49 |
|
|